Lento Bio Raises $680,000 In Oversubscribed Seed Round Led By Ichor Life Sciences
09/06/22, 1:32 PM
Location
potsdamMoney raised
$680,000
Industry
therapeutics
biotechnology
health care
Round Type
seed
POTSDAM, NY / September 6, 2022 / Lento Bio, Inc., a preclinical pharmaceutical company developing small-molecule therapeutics to restore ocular lens flexibility and near-vision in presbyopia patients, announced today they have raised $680,000 in funding during their recent oversubscribed seed round. Ichor Life Sciences is the lead investor for the round, providing $400,000 in funding to Lento Bio.
Company Info
Location
main street
potsdam, brandenburg, germany
Additional Info
Lento Bio is an Ichor portfolio company developing small-molecule therapeutic treatments for degenerative aging disorders, focused initially on developing AGE-breaking therapeutic eyedrops for presbyopia. Lento Bio was founded in 2022 and is headquartered in Potsdam, N.Y. For more information go to lentobio.com.